Jpmorgan Chase & CO Neuronetics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Neuronetics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 497 shares of STIM stock, worth $482. This represents 0.0% of its overall portfolio holdings.

Number of Shares

497

Previous 4,212 88.2%

Holding current value

$482

Previous $7,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$0.73 - $2.0 $2,711 - $7,430	-3,715 Reduced 88.2%	497 $0
Q2 2024 Aug 12, 2024	BUY	$1.73 - $4.81 $7,227 - $20,096	4,178 Added 12288.24%	4,212 $7,000
Q1 2024 May 10, 2024	SELL	$2.68 - $4.8 $1,752 - $3,139	-654 Reduced 95.06%	34 $0
Q4 2023 Feb 12, 2024	BUY	$1.05 - $2.9 $666 - $1,841	635 Added 1198.11%	688 $1,000
Q3 2023 Nov 14, 2023	SELL	$1.29 - $2.22 $1,466 - $2,524	-1,137 Reduced 95.55%	53 $0
Q2 2023 Aug 11, 2023	SELL	$2.07 - $2.92 $32,937 - $46,463	-15,912 Reduced 93.04%	1,190 $2,000
Q1 2023 May 11, 2023	BUY	$2.81 - $6.71 $21,774 - $51,995	7,749 Added 82.85%	17,102 $49,000
Q4 2022 Feb 13, 2023	BUY	$2.74 - $6.87 $3,819 - $9,576	1,394 Added 17.51%	9,353 $64,000
Q3 2022 Nov 14, 2022	BUY	$2.35 - $4.66 $10,290 - $20,406	4,379 Added 122.32%	7,959 $25,000
Q2 2022 Aug 11, 2022	SELL	$2.09 - $3.71 $17,599 - $31,241	-8,421 Reduced 70.17%	3,580 $11,000
Q1 2022 May 11, 2022	SELL	$2.84 - $4.52 $31,805 - $50,619	-11,199 Reduced 48.27%	12,001 $36,000
Q4 2021 Feb 10, 2022	BUY	$3.87 - $6.59 $51,695 - $88,029	13,358 Added 135.72%	23,200 $104,000
Q3 2021 Nov 12, 2021	BUY	$6.22 - $15.54 $61,217 - $152,944	9,842 New	9,842 $64,000

Others Institutions Holding STIM

# of Institutions

Shares Held

13.1M

Call Options Held

30.1K

Put Options Held

View Full List

About Neuronetics, Inc.

Ticker STIM
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 27,022,800
Market Cap $26.2M
Description
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive diso...

More about STIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Neuronetics, Inc. Transaction History